Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Net Margin (2016 - 2025)

Historic Net Margin for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to 492.45%.

  • Ocular Therapeutix's Net Margin fell 2055300.0% to 492.45% in Q4 2025 from the same period last year, while for Dec 2025 it was 507.2%, marking a year-over-year decrease of 2481500.0%. This contributed to the annual value of 507.2% for FY2025, which is 2481500.0% down from last year.
  • According to the latest figures from Q4 2025, Ocular Therapeutix's Net Margin is 492.45%, which was down 2055300.0% from 467.35% recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Net Margin ranged from a high of 142.09% in Q3 2023 and a low of 589.6% during Q1 2025
  • For the 5-year period, Ocular Therapeutix's Net Margin averaged around 259.05%, with its median value being 189.7% (2021).
  • Its Net Margin has fluctuated over the past 5 years, first skyrocketed by 10600100bps in 2021, then tumbled by -3747200bps in 2025.
  • Ocular Therapeutix's Net Margin (Quarter) stood at 160.25% in 2021, then grew by 8bps to 147.67% in 2022, then dropped by -4bps to 153.65% in 2023, then crashed by -87bps to 286.92% in 2024, then tumbled by -72bps to 492.45% in 2025.
  • Its Net Margin stands at 492.45% for Q4 2025, versus 467.35% for Q3 2025 and 499.31% for Q2 2025.